Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL4871106 (M-2698, M2698, Msc-2363318a, MSC-2363318A, MSC2363318A) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
aurora kinase B/Aurora kinase B/Inner centromere protein in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL3430907] [GtoPdb: 1937] [UniProtKB: Q96GD4, Q9NQS7] | ||||||||
ChEMBL | Inhibition of recombinant full length GST-tagged human Aurora B (1 to 344 residues) co-expressed with N-terminal His-tagged human recombinant INCENP (803 to 918 residues) in baculovirus infected Sf21 cells incubated for 90 mins by mobility shift assay | B | 6.77 | pIC50 | 170 | nM | IC50 | J Med Chem (2021) 64: 14603-14619 [PMID:34596404] |
AKT serine/threonine kinase 1/Serine/threonine-protein kinase AKT in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4282] [GtoPdb: 1479] [UniProtKB: P31749] | ||||||||
ChEMBL | Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay | B | 8.4 | pIC50 | 4 | nM | IC50 | J Med Chem (2021) 64: 14603-14619 [PMID:34596404] |
GtoPdb | - | - | 9 | pIC50 | 1 | nM | IC50 | Am J Cancer Res (2016) 6: 806-18 [PMID:27186432] |
ribosomal protein S6 kinase B1 in Human [GtoPdb: 1525] [UniProtKB: P23443] | ||||||||
GtoPdb | - | - | 9 | pIC50 | 1 | nM | IC50 | Am J Cancer Res (2016) 6: 806-18 [PMID:27186432] |
AKT serine/threonine kinase 3 in Human [GtoPdb: 2286] [UniProtKB: Q9Y243] | ||||||||
GtoPdb | - | - | 9 | pIC50 | 1 | nM | IC50 | Am J Cancer Res (2016) 6: 806-18 [PMID:27186432] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]